Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Alpine's mission is to become the world's leading developer of novel immunotherapies for challenging and underserved diseases.

Alpine’s vision is to be renowned for delivering its innovative immunotherapies to a broad range of severe diseases, thereby improving the lives of patients around the world.

Alpine Immune Sciences has been recognized with several prestigious awards and grants, including the 2017 Biotechnology Innovation Award from the National Institutes of Health and the 2019 Science in Seattle Award from Seattle Science Foundation.